PROTOKOLwiki
COMPOUNDS / COGNITIVE / MEXIDOL
COGNITIVE

MEXIDOL

MEDIUM RISK
BEST FOR:Cognition●●●●●●●○○○7/10
MEXIDOL · EMOXYPINE · ETHYLMETHYLHYDROXYPYRIDINE SUCCINATE · EMHPS · MEXICOR · ARMADIN · ARMADIN LONG · MEXIDOL FORTE 250
NootropicAntioxidantNeuroprotectiveWithdrawal SupportAnxiolyticSoviet / Russian

Russian neurometabolic antioxidant drug (emoxypine succinate) used for cognitive impairment, stroke recovery, and alcohol/phenibut withdrawal.

ROUTE / DOSAGE
LOW125mg
STANDARD250-500mg
HIGH750mg+
Note: Mexidol Forte 250 tablets; typically 1 tab 3x/day. Take with meals.
CYCLE
2-6 week course repeat after 1-3 months
BIOAVAILABILITY
~50% oral high parenteral (IV/IM)
ACTIVE DURATION
4-6h (subjective)
STORAGE
Room temperature dry away from light injectable form store below 25°C
DURATION BREAKDOWN
Total4-6h
Onset30min-1h
Come up30-60 min
Peak1-2h
Offset2-3h
After effects2-4h
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
8 documented
Helps while tapering off or PAWS for/from Phenibut/Alchool
Reduces oxidative stress and lipid peroxidation
Improves cognitive function in cerebrovascular disease
Enhances mitochondrial energy metabolism via succinate
Reduces neuroinflammation and neuronal damage in ischemia
Attenuates alcohol withdrawal symptoms
Improves sleep quality and reduces asthenia
May enhance athletic endurance and hypoxia tolerance
§ 02 — RISKS
Limited Western regulatory oversight; not FDA or EMA approved
Nearly all clinical evidence from Russian institutions with risk of publication bias
Significant statistical heterogeneity across meta-analyses limits certainty
Potential ergogenic effects may constitute doping violation under WADA rules
Unknown long-term safety profile in healthy populations
Possible allergic reactions and gastrointestinal side effects
§ 03 — INTERACTIONS
No interaction with your stack
VIEW STACK
SAFE · SYNERGISTIC
Phenibut
§ 04 — SCIENCE

A meta-analysis of 10 prospective randomized trials (482 patients) demonstrated statistically and clinically significant improvement in cognitive function (MoCA scale, effect size 2.06, p=0.0002) in patients with chronic brain ischemia. A systematic review of 11 studies showed positive effects on ischemic stroke outcomes with significant NIHSS and modified Rankin scale reductions. Clinical studies also support use in post-COVID syndrome, ADHD in children, and alcohol intoxication recovery. However, nearly all published studies originate from Russian institutions with limited independent Western replication, and significant statistical heterogeneity has been noted across trials. The compound is not approved by FDA or EMA, and a 2024 analysis flagged its ergogenic potential as warranting possible WADA prohibition consideration.

§ 06 — SOURCES
[]
Official Mexidol Website
mexidol.ru ↗
[1]
Mexidol, Cytoflavin, and succinic acid derivatives as antihypoxic, anti-ischemic metabolic modulators, and ergogenic aids in athletes
pubmed.ncbi.nlm.nih.gov ↗
[2]
Possibilities of using Mexidol in the complex therapy of mental disorders
pubmed.ncbi.nlm.nih.gov ↗
[3]
Efficacy of Mexidol in combination with cerebral revascularization in the treatment of ischemic stroke
pubmed.ncbi.nlm.nih.gov ↗
[4]
Combined administration of mexidol with known medicines
pubmed.ncbi.nlm.nih.gov ↗
[5]
The use of Mexidol in patients with mild (moderate) cognitive impairment: results of a meta-analysis
pubmed.ncbi.nlm.nih.gov ↗
[6]
The possibilities of Mexidol usage in neuropediatrics
pubmed.ncbi.nlm.nih.gov ↗
[7]
The impact of therapy with Mexidol on neurological deficit and functional outcome in patients with ischemic stroke: a systematic review and meta-analysis
pubmed.ncbi.nlm.nih.gov ↗
[8]
Efficacy of Mexidol in the correction of postcovid syndrome in patients with chronic cerebrovascular diseases
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT